What were the Q2 2025 revenue and earnings numbers, and how do they compare to analysts’ expectations? | PHAT (Aug 07, 2025) | Candlesense
PHAT

What were the Q2 2025 revenue and earnings numbers, and how do they compare to analysts’ expectations?

Answer

The press release you referenced announces Phathom Pharmaceuticals’ second‑quarter 2025 (Q2 2025) results, but the excerpt you provided does not include the actual revenue or earnings figures, nor does it provide analysts’ consensus estimates for those metrics. Consequently, based on the information supplied, I cannot give you the specific Q2 2025 revenue, earnings per share (EPS), or how those numbers stacked up against analysts’ expectations.

If you have access to the full press‑release text (or a more detailed news story) that includes the numerical results and analyst expectations, feel free to share those details and I’ll be happy to give you a precise comparison. Otherwise, you may need to consult the full press release on the company’s website, the SEC filing (Form 10‑Q), or a financial news service that reported the numbers.

Other Questions About This News

How does Phathom’s current valuation multiples (e.g., EV/EBITDA, P/E, price‑to‑sales) compare to other GI‑focused biotech competitors? What is the projected impact on the company’s cash runway and capital‑raising needs going forward? How does the company’s operating cash burn and net cash position compare to the same period last year and to its cash runway expectations? What impact do any new licensing, partnership, or acquisition agreements announced in the release have on future revenue and profitability? How sensitive is the stock to potential dilution from upcoming equity raises, convertible debt, or warrant exercises? Are there any upcoming regulatory decisions or FDA filings that could materially affect the stock price? How does this earnings release affect analyst consensus target prices and rating changes? Which clinical trial milestones were achieved in Q2, and what are the timelines for upcoming data releases or FDA submissions? What risk factors were highlighted in the earnings release that could influence the near‑term outlook or stock volatility? What were the primary drivers of any revenue growth or decline in the quarter (e.g., product sales, licensing revenue, collaborations)? What guidance did Phathom provide for FY2025 and FY2026 revenue, earnings, and cash flow, and how does it compare to prior guidance?